Amedisys Board of Directors Authorizes $100 Million Stock Repurchase Program
BATON ROUGE, La., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, today announced that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $100 million of its outstanding common stock through December 31, 2023.
- BATON ROUGE, La., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, today announced that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $100 million of its outstanding common stock through December 31, 2023.
- Scott Ginn, Acting Chief Operating Officer and Chief Financial Officer, stated, “Given our strong cashflow and low leverage, we feel it is prudent to have authorization to buy-back shares throughout the course of the year.
- This will become a recurring part of our capital deployment strategy; however, our priorities will continue to be accretive acquisitions in both Home Health and Hospice and building our High-Acuity Care joint ventures.”
Under the stock repurchase program, the Company may repurchase its common stock from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions and other considerations and in accordance with applicable federal securities laws and other legal requirements. - The Company's repurchases may be executed using open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a 10b5-1 trading plan.